Multi-center investigation of the clinical and pathological characteristics of inflammatory breast cancer based on Chinese Society of Breast Surgery (CSBrs-007).

CONCLUSION: Our study provides novel insight into clinicopathological characteristics and treatment status among patients with IBC in China, and might provide a direction and basis for further studies. TRIAL REGISTRATION: chictr.org.cn, No. ChiCTR1900027179; http://www.chictr.org.cn/showprojen.aspx?proj=45030. PMID: 32925286 [PubMed - as supplied by publisher]
Source: Chinese Medical Journal - Category: General Medicine Authors: Tags: Chin Med J (Engl) Source Type: research

Related Links:

AbstractBackgroundInflammatory breast cancer (IBC) is a rare and aggressive disease treated with multimodality therapy: preoperative systemic therapy (PST) followed by modified radical mastectomy (MRM), chest wall and regional nodal radiotherapy, and adjuvant biologic therapy and/or endocrine therapy when appropriate. In non-IBC, the degree of pathologic response to PST has been shown to correlate with time to recurrence (TTR) and overall survival (OS). We sought to determine if pathologic response correlates with oncologic outcomes of IBC patients.MethodsFollowing review of IBC patients ’ records (1997–2014), ...
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
Abstract BACKGROUND: Inflammatory breast cancer (IBC) is a rare and aggressive disease treated with multimodality therapy: preoperative systemic therapy (PST) followed by modified radical mastectomy (MRM), chest wall and regional nodal radiotherapy, and adjuvant biologic therapy and/or endocrine therapy when appropriate. In non-IBC, the degree of pathologic response to PST has been shown to correlate with time to recurrence (TTR) and overall survival (OS). We sought to determine if pathologic response correlates with oncologic outcomes of IBC patients. METHODS: Following review of IBC patients' records (1997-...
Source: Ann Oncol - Category: Cancer & Oncology Authors: Tags: Ann Surg Oncol Source Type: research
Conditions:   HER2/Neu Negative;   Recurrent Inflammatory Breast Carcinoma;   Stage IV Breast Cancer;   Stage IV Inflammatory Breast Carcinoma Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab Sponsors:   Northwestern University;   Bristol-Myers Squibb;   National Cancer Institute (NCI) Not yet recruiting - verified September 2016
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusions:FO utilization is variable based on MBC sub-type and the timing of tissue collection is bimodal. ESR1 mutations were associated with history of prolonged endocrine rx treatment in ER+ IDC and CDH1 mutations were associated with ILC. FO assays frequently influenced clinical treatment decisions but did not result in a high number of pts enrolled on clinical trials. We will update our dataset with additional FO assays and clinicopathologic variables.Citation Format: Harnden KK, Kimmick GG, Marcom PK, Westbrook KE, Blackwell KL. The foundation one assay influences clinical decision making in metastatic breast cance...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
Conclusions: This phase I trial shows that romidepsin and nab-paclitaxel are well-tolerated in patients with advanced IBC. The MTD and recommended dose of romidepsin is 10 mg/m2 with nab-paclitaxel 100 mg/ m2 days 1, 8, 15 of a 28 day cycle. A phase II trial is planned in recurrent HER negative IBC patients.Citation Format: Avery TP, Jaslow R, Basu-Mallick A, Zibelli A, Fellin F, Cristofanilli M. A phase I study of romidepsin in combination with nab-paclitaxel in patients with metastatic HER-2 negative inflammatory breast cancer (IBC). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Can...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
Conditions:   Inflammatory Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of BreastInterventions:   Drug: Eribulin;   Drug: Adriamycin;   Drug: CyclophosphamideSponsors:   Dana-Farber Cancer Institute;   Eisai Inc.Not yet recruiting - verified December 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Breast Carcinoma | Breast Surgery | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | China Health | General Medicine | HER2 | Hormones | Inflammatory Breast Cancer | Mastectomy | Molecular Biology | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Study